| Cancer-related molecular mechanisms research | Lifetime | 98 | US 39 | 99.47 |
| Circular RNAs in diseases | Lifetime | 51 | US 15 | 99.41 |
| MicroRNA in disease regulation | Lifetime | 119 | US 44 | 99.42 |
| RNA modifications and cancer | Lifetime | 424 | US 239 | 99.08 |
| RNA Interference and Gene Delivery | Lifetime | 574 | US 241 | 98.47 |
| Epigenetics and DNA Methylation | Lifetime | 801 | US 419 | 98.19 |
| RNA Research and Splicing | Lifetime | 876 | US 481 | 97.73 |
| Cancer-related gene regulation | Lifetime | 532 | US 251 | 97.47 |
| Histone Deacetylase Inhibitors Research | Lifetime | 296 | US 166 | 97.09 |
| Cancer-related Molecular Pathways | Lifetime | 907 | US 455 | 97.11 |
| Ferroptosis and cancer prognosis | Lifetime | 871 | US 181 | 92.96 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 963 | US 507 | 93.50 |
| Cancer Mechanisms and Therapy | Lifetime | 991 | US 375 | 91.64 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 953 | US 376 | 90.10 |
| Sirtuins and Resveratrol in Medicine | Lifetime | 956 | US 256 | 86.58 |
| FOXO transcription factor regulation | Lifetime | 554 | US 237 | 82.04 |
| RNA modifications and cancer | 2021-2025 | 104 | US 25 | 98.83 |
| Cancer-related molecular mechanisms research | 2021-2025 | 112 | US 11 | 98.86 |
| Cancer-related gene regulation | 2021-2025 | 55 | US 16 | 95.65 |
| Epigenetics and DNA Methylation | 2021-2025 | 273 | US 95 | 95.40 |
| MicroRNA in disease regulation | 2021-2025 | 493 | US 47 | 94.72 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 490 | US 218 | 95.77 |
| Acute Myeloid Leukemia Research | 2021-2025 | 534 | US 251 | 95.28 |
| Ferroptosis and cancer prognosis | 2021-2025 | 557 | US 48 | 93.09 |
| Circular RNAs in diseases | 2021-2025 | 393 | US 22 | 92.22 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 231 | US 19 | 88.13 |
| Erythrocyte Function and Pathophysiology | 2021-2025 | 187 | US 70 | 88.52 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 612 | US 121 | 87.60 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 344 | US 128 | 81.40 |
| Viral-associated cancers and disorders | 2021-2025 | 982 | US 350 | 76.82 |
| Blood disorders and treatments | 2021-2025 | 581 | US 138 | 68.52 |
| Genomics, phytochemicals, and oxidative stress | 2021-2025 | 887 | US 78 | 68.45 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 942 | US 306 | 66.49 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 720 | US 130 | 63.52 |
| T-cell and Retrovirus Studies | 2021-2025 | 919 | US 191 | 59.11 |
| Protein Tyrosine Phosphatases | 2021-2025 | 518 | US 159 | 54.55 |
| Bioactive natural compounds | 2021-2025 | 833 | US 27 | 24.66 |